drugset / Trial / NCT03252808
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.
Timeline
- Start
- 2017-09-25
- Primary completion
- 2020-02-19
- Completion
- 2035-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CANERPATUREV | Other / unclassified | 1e+06 unknown | Other |
| Subject | CANERPATUREV | Other / unclassified | 1e+07 unknown | Other |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Background | S-1 | Small molecule | 40 mg/m2 | Oral |
| Background | S-1 | Small molecule | 60 mg/m2 | Oral |